Project Details
Description
DESCRIPTION (provided by applicant):
MSKCC has made a major commitment to translational research in prostate
cancer, recruited new faculty, constructed new facilities, and provided
substantial pilot funding for translational research projects. MSKCC cares
for a large population of patients (less than 1400/yr) with all stages of
prostate cancer. While ethnic minorities are under represented, the large
prostate cancer population assures sufficient minority patients eligible for
SPORE investigations. Our strategy is to develop risk-adjusted therapies
targeted to the characteristics of individual cancers. Translational research
objectives are to: 1) develop predictive models of the natural history of
localized cancer to improve patient decision-making and treatment selection,
2) determine critical molecular and genetic mechanisms of progression and
metastasis; 3) develop risk-adjusted therapy for progression after local
treatment using immunologic (PSMA-targeted vaccines) and other biologic
agents; and 4) develop new mechanism-based therapy for advanced cancers.
These goals will be addressed through 4 research projects (Population-based
study of natural history, Molecular carcinogenesis, DNA vaccines, and
Experimental therapeutics) supported by 6 cores (Pathology and tissue bank,
Informatics, Animal models, Animal imaging, DNA arrays, and Administration),
and Developmental Research (pilot projects) and Career Development components.
The applied and basic scientists are organized into 3 multidisciplinary
Translational Working Groups: Clinical Outcomes and Prognosis, Molecular
Mechanisms and Markers, and Experimental Therapeutics. This SPORE addresses
key research priorities of the NCI's Prostate Cancer Progress Review Group:
new animal models, molecular mechanisms of carcinogenesis and invasion,
validation of prognostic markers, and new targets for therapy. An MSKCC SPORE
can provide NCI with a large patient population and frozen tissue bank, a
history of active participation in clinical trials, a multidisciplinary team
of clinicians and scientists successfully collaborating, an expanding basic
research program, and advanced experimental therapeutics. The ultimate goal
is to bring basic discoveries regarding mechanisms of prostate cancer
development and progression to the clinic. With SPORE support, MSKCC can
expand its approaches to the prevention, diagnosis, and treatment of prostate
cancer to eventually reduce morbidity and mortality from this disease.
Status | Finished |
---|---|
Effective start/end date | 9/14/01 → 8/31/02 |
ASJC
- Drug Discovery
- Computers in Earth Sciences
- Software
- Urology
- Information Systems
- Medical Laboratory Technology
- Instrumentation
- Bioengineering
- Genetics
- Health Information Management
- Molecular Medicine
- Oncology(nursing)
- Health Informatics
- Molecular Biology
- Radiological and Ultrasound Technology
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
- Industrial and Manufacturing Engineering
- Epidemiology
- Histology
- Pharmacology
- Microbiology
- Immunology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.